

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Romiplostim for the treatment of chronic idiopathic (immune) thrombocytopenic purpura

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No issues were identified during scoping.
---

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No equalities issues were raised in the submissions, expert statements or academic report.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

The Committee was aware that certain religious groups would not consent to the use of blood products, and that ITP might affect pre-menopausal women more than men. The Committee also understood that romiplostim might reduce the burden of hospital admission for long hours to receive intravenous immunoglobulin, especially for people for whom it is difficult to travel to a hospital. The Committee noted that no specific representations had been made for these groups of people.
---

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The Committee concluded that its preliminary recommendations do account for the individual needs of people to receive romiplostim, and do not make it more difficult for any particular group to access the treatment with romiplostim compared with any other group.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

No barriers to access were identified.

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The Committee's considerations of equality issues are described in section 4.18 of the appraisal consultation document.

**Approved by Associate Director (name):** Elisabeth George

**Date:** 23 11 10

**Final appraisal determination**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional equality issues were raised.

2. If the recommendations have changed after consultation, are there

any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?  
If so, what are the barriers to access for the specific group?

Not applicable.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's considerations of equality issues are described in section 4.19 of the final appraisal determination.

**Approved by Centre or Programme Director (name):** ...Meindert Boysen...

**Date:** 01/03/2011